Dopamine Transporter EL-2 Polyclonal Antibody

Product Description

Dopamine Transporter EL-2 Polyclonal Antibody
Catalog number: B2013225
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 uL
Molecular Weight or Concentration: WB, IHC 1:1000
Supplied as: Solution
Applications: molecular tool for various biochemical applications
Storage: -20° C
Keywords: Dopamine Transporter EL-2 pAB
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D’Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Trial of Prasinezumab in Early-Stage Parkinson’s Disease N Engl J Med. 2022 Aug 4;387(5):421-432.
2: Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, Postuma RB, Simon DK, Tolosa E, Mollenhauer B, Cedarbaum JM, Fraser K, Xiao J, Evans KC, Graham DL, Sapir I, Inra J, Hutchison RM, Yang M, Fox T, Budd Haeberlein S, Dam T; SPARK Investigators. Trial of Cinpanemab in Early Parkinson’s Disease N Engl J Med. 2022 Aug 4;387(5):408-420.
3: Foster JD, Vaughan RA. Phosphorylation mechanisms in dopamine transporter regulation J Chem Neuroanat. 2017 Oct;83-84:10-18.
4: Eriksen J, Jørgensen TN, Gether U. Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges J Neurochem. 2010 Apr;113(1):27-41.
5: Chahine LM, Beach TG, Brumm MC, Adler CH, Coffey CS, Mosovsky S, Caspell-Garcia C, Serrano GE, Munoz DG, White CL 3rd, Crary JF, Jennings D, Taylor P, Foroud T, Arnedo V, Kopil CM, Riley L, Dave KD, Mollenhauer B; Systemic Synuclein Sampling Study. In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease Neurology. 2020 Sep 1;95(9):e1267-e1284.
6: Buttarelli FR, Capriotti G, Pellicano C, Prosperi D, Circella A, Festa A, Giovannelli M, Tofani A, Pontieri FE, Scopinaro F. Central and peripheral dopamine transporter reduction in Parkinson’s disease Neurol Res. 2009 Sep;31(7):687-91.
7: Cheng Z, Zhong YM, Yang XL. Expression of the dopamine transporter in rat and bullfrog retinas Neuroreport. 2006 May 29;17(8):773-7.
8: Freed C, Revay R, Vaughan RA, Kriek E, Grant S, Uhl GR, Kuhar MJ. Dopamine transporter immunoreactivity in rat brain J Comp Neurol. 1995 Aug 21;359(2):340-9.
9: Delis F, Mitsacos A, Giompres P. Pharmacological characterization and anatomical distribution of the dopamine transporter in the mouse cerebellum Cerebellum. 2008;7(3):242-51.
10: Fricks-Gleason AN, German CL, Hoonakker AJ, Friend DM, Ganesh KK, Carver AS, Hanson GR, Fleckenstein AE, Keefe KA. An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity Synapse. 2016 Apr;70(4):139-46.

Products Related to Dopamine Transporter EL-2 Polyclonal Antibody can be found at Antibodies